In prostate cancer, mutated Speckle type POZ protein (SPOP) leads to impaired degradation and upregulation of BRD4 protein which confers intrinsic resistance to BET inhibitors (Janouskova et al., 2017; Dai et al., 2017; Zhang et al., 2017). This evidence concerns the gene DNER and prostate carcinoma.